Shares of Insys Therapeutics Inc. (NASDAQ:INSY) were up 6.4% on Tuesday . The stock traded as high as $19.20 and last traded at $18.91, with a volume of 562,859 shares. The stock had previously closed at $17.77.

Several analysts recently commented on INSY shares. Jefferies Group reiterated a “buy” rating and issued a $22.00 price target (up previously from $17.00) on shares of Insys Therapeutics in a research report on Thursday, August 4th. Janney Montgomery Scott started coverage on shares of Insys Therapeutics in a research report on Thursday, April 14th. They issued a “buy” rating and a $22.00 price target for the company. Zacks Investment Research upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, June 29th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Insys Therapeutics in a research report on Monday, April 11th. Finally, Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, April 12th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $24.67.

The stock has a market cap of $1.39 billion and a P/E ratio of 29.19. The stock’s 50-day moving average is $14.79 and its 200 day moving average is $15.76.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.01. The business had revenue of $67.10 million for the quarter, compared to the consensus estimate of $66.90 million. During the same period last year, the business earned $0.21 earnings per share. The firm’s quarterly revenue was down 13.6% compared to the same quarter last year. Equities analysts anticipate that Insys Therapeutics Inc. will post $0.37 earnings per share for the current fiscal year.

In other news, Director Theodore H. Stanley sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $16.27, for a total transaction of $260,320.00. Following the completion of the sale, the director now owns 18,000 shares of the company’s stock, valued at $292,860. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 50,000 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were bought at an average cost of $12.84 per share, with a total value of $642,000.00. Following the transaction, the insider now directly owns 31,982 shares of the company’s stock, valued at approximately $410,648.88. The disclosure for this purchase can be found here.

Several hedge funds recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock worth $1,249,000 after buying an additional 754 shares during the last quarter. Bank of Montreal Can increased its stake in Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock worth $1,909,000 after buying an additional 5,733 shares during the last quarter. Globeflex Capital L P increased its stake in Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock worth $1,135,000 after buying an additional 39,600 shares during the last quarter. Airain ltd bought a new stake in Insys Therapeutics during the fourth quarter worth $1,309,000. Finally, California Public Employees Retirement System increased its stake in Insys Therapeutics by 178.7% in the fourth quarter. California Public Employees Retirement System now owns 97,000 shares of the specialty pharmaceutical company’s stock worth $2,777,000 after buying an additional 62,200 shares during the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.